beta-Endorphin (trifluoroacetate salt) Biochemical

beta-Endorphin (1-27)(human)(trifluoroacetate salt)

Cat. Num. AAA227392

• Purity: 98%
• Synonyms: beta-Endorphin (trifluoroacetate salt); N/A; beta-Endorphin (1-27)(human)(trifluoroacetate salt); beta-Endorphin (trifluoroacetate salt) biochemical

• Purity/Purification: 98%

• Solubility: DMSO: 1 mg/mL; <1mg/ml refers to the product slightly soluble or insoluble
• Preparation and Storage: Powder: -20 degree C for 3 years; In solvent: -80 degree C for 2 years

Structure

(beta-Lactamase-IN-5, CAS 1463521-39-2)

Structure

(beta-Lactamase-IN-5, CAS 1463521-39-2)

Related Product Information for beta-Endorphin (trifluoroacetate salt) biochemical

beta-Endorphin (1-27) is an endogenous peptide that binds to u-, delta-, and kappa-opioid receptors (Kis = 5.31, 6.17, and 39.82 nM, respectively, in COS-1 cells expressing rat receptors). It binds to rat and mouse brain membrane preparations (IC50s = 1.1 and 5.7 nM, respectively) and induces chemotaxis of human monocytes in vitro when used at a concentration of 1 nM. Intracerebroventricular administration of beta-endorphin (1-27) increases the latency to tail withdrawal in response to thermal stimulation in mice with a median antinociceptive dose (AD50) of 1,500 pmol per animal. It inhibits antinociception induced by beta-endorphin in mice in response to thermal stimuli when administered at a dose of 65 pmol per animal. In rats, beta-endorphin (1-27) does not affect drug-associated place preference when administered at doses up to 20 ug, i.c.v., but inhibits beta-endorphin-induced place preference when administered at a dose of 10 ug per animal.

References

1. Gu YG, et, al. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors. WO2013149121A1.